Drugs / RBMRNA-176
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05903118 | Jan → Sep 2022 | COVID-19 | Argorna Pharmaceuticals Co., LTD | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBMRNA-176 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05903118 ↗ |
| Modality | Messenger RNA (mRNA) | “SARS-CoV-2 mRNA Vaccine” NCT05903118 ↗ |
| Route | Intramuscular | “administered as intramuscular injection” NCT05903118 ↗ |